Amalgamated Bank Has $4.84 Million Stock Position in Bruker Co. (NASDAQ:BRKR)

Amalgamated Bank lessened its stake in Bruker Co. (NASDAQ:BRKR) by 10.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,833 shares of the medical research company’s stock after selling 8,028 shares during the quarter. Amalgamated Bank’s holdings in Bruker were worth $4,837,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of BRKR. Commonwealth Equity Services LLC lifted its stake in shares of Bruker by 11.0% during the third quarter. Commonwealth Equity Services LLC now owns 13,259 shares of the medical research company’s stock valued at $826,000 after acquiring an additional 1,312 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Bruker by 58.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 41,233 shares of the medical research company’s stock worth $2,569,000 after purchasing an additional 15,137 shares in the last quarter. Park Avenue Securities LLC acquired a new stake in Bruker during the 3rd quarter worth approximately $266,000. Inspire Investing LLC bought a new position in Bruker in the third quarter valued at approximately $321,000. Finally, TD Asset Management Inc increased its position in shares of Bruker by 2.6% during the third quarter. TD Asset Management Inc now owns 1,102,095 shares of the medical research company’s stock worth $68,661,000 after acquiring an additional 28,031 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Hermann Fritz Requardt sold 15,000 shares of Bruker stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the completion of the sale, the director now owns 23,147 shares of the company’s stock, valued at approximately $2,084,618.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 28.30% of the company’s stock.

Analyst Ratings Changes

BRKR has been the topic of a number of recent research reports. Stifel Nicolaus lifted their target price on Bruker from $63.00 to $81.00 and gave the company a “hold” rating in a research report on Wednesday, February 14th. The Goldman Sachs Group increased their target price on shares of Bruker from $66.00 to $74.00 and gave the stock a “sell” rating in a report on Wednesday, April 10th. Citigroup lifted their price target on shares of Bruker from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. JPMorgan Chase & Co. upgraded shares of Bruker from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $60.00 to $90.00 in a research note on Wednesday, February 14th. Finally, UBS Group lifted their target price on Bruker from $94.00 to $102.00 and gave the company a “buy” rating in a research report on Friday, March 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $84.86.

Bruker Stock Up 2.5 %

Shares of BRKR stock opened at $74.33 on Wednesday. Bruker Co. has a 52-week low of $53.79 and a 52-week high of $94.86. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.91 and a current ratio of 1.81. The stock has a market cap of $10.80 billion, a price-to-earnings ratio of 27.03, a PEG ratio of 1.73 and a beta of 1.22. The firm’s 50-day moving average is $86.98 and its 200-day moving average is $75.44.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.07. The firm had revenue of $721.70 million for the quarter, compared to analyst estimates of $729.88 million. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.64 earnings per share. Sell-side analysts predict that Bruker Co. will post 2.82 EPS for the current year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were issued a $0.05 dividend. The ex-dividend date was Thursday, February 29th. This represents a $0.20 annualized dividend and a dividend yield of 0.27%. Bruker’s dividend payout ratio is currently 7.27%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.